Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers
{{output}}
Background: Nemtabrutinib is a reversible inhibitor of both wild-type and acquired resistance-related mutant BTK. Since nemtabrutinib biochemically inhibits various kinases, new drug response biomarkers, cross-reactivities and di... ...
